Source comparison
TB-500 for Athletes: Protocol Comparisons
Acute soft-tissue injury (muscle strain, tendon microtear) 2–2.5mg twice weekly for 4–6 weeks, subcutaneous administration 250–500mcg daily, localized injection near injury site Not applicable for acute recovery. GH acts on synthesis timelines (weeks to months
This comparison does not assign a generated winner or score.
- Acute soft-tissue injury (muscle strain, tendon microtear)
- 2–2.5mg twice weekly for 4–6 weeks, subcutaneous administration
- 250–500mcg daily, localized injection near injury site
- Not applicable for acute recovery. GH acts on synthesis timelines (weeks to months)
- TB-500 addresses structural repair; BPC-157 stabilizes vasculature. Combined protocols show faster return-to-activity in observational research.
- Chronic tendinopathy or overuse injury
- 2mg weekly maintenance dose after initial loading phase
- 250mcg daily for 8–12 weeks, then reduce to 3–4× weekly
- 2–4 IU daily split-dose to support baseline collagen synthesis
- Chronic injuries require longer timelines. TB-500 loading phase (6 weeks) followed by maintenance reduces flare-ups. GH supports tissue quality but does not replace actin-mediated repair.
- Post-surgical recovery (ligament reconstruction, tendon repair)
- 2.5mg twice weekly starting 48 hours post-op for 6–8 weeks
- 500mcg daily for 4 weeks post-op, then taper to 250mcg
- Not recommended during acute healing phase. Resume 4–6 weeks post-op if used for baseline tissue support
- TB-500's angiogenic effect is most valuable during the proliferative phase (days 3–21 post-injury). BPC-157 reduces inflammation without suppressing immune response.
- General recovery and injury prevention
- Not recommended for injury-free athletes. TB-500 acts on damaged tissue, not healthy baseline
- 250mcg 3–4× weekly as maintenance
- 2 IU nightly to support collagen turnover and tissue quality
- TB-500 is injury-responsive, not preventative. Athletes without acute damage see no meaningful benefit. GH and BPC-157 maintenance protocols address baseline tissue health.